Background

Hyperviscosity syndrome refers to a clinical condition characterized by an increase in the viscosity (thickness or stickiness) of the blood due to a high concentration of macromolecules, such as proteins or lipids.

This increase in blood viscosity can impede normal blood flow and lead to clinical symptoms and complications. Hyperviscosity syndrome is most commonly associated with conditions that result in the overproduction or excessive accumulation of specific blood components.

Epidemiology

Hyperviscosity syndrome is not a specific disease but a clinical condition that can occur as a result of various underlying disorders, primarily hematological and metabolic conditions. Therefore, its epidemiology is closely tied to the prevalence and incidence of the conditions that lead to hyperviscosity. Here’s an overview of the epidemiology of some of the key conditions associated with hyperviscosity syndrome:

Multiple Myeloma:

• Multiple myeloma is a relatively rare cancer, accounting for about 1% of all cancers and 10% of hematologic malignancies.
• It is more common in older adults, with a median age at diagnosis around 66 years.
• There is a slightly higher incidence in males compared to females.

Waldenström Macroglobulinemia:

• Waldenström macroglobulinemia is a rare condition, representing approximately 1-2% of hematologic malignancies.
• It typically affects older adults, with a median age at diagnosis in the 60s or 70s.
• The incidence is slightly higher in males than in females.

Polycythemia Vera:

• Polycythemia vera is a relatively rare myeloproliferative neoplasm.
• The incidence increases with age and is more common in individuals over 60 years old.
• It is slightly more common in men than in women.

Cryoglobulinemia:

• Cryoglobulinemia can be associated with various underlying conditions, including hepatitis C virus (HCV) infection.
• The epidemiology of cryoglobulinemia depends on the prevalence of these underlying conditions, with HCV-related cryoglobulinemia being more common in regions with a higher prevalence of HCV infection.

Hyperlipidemia:

• Hyperlipidemia, particularly elevated triglyceride levels, can contribute to hyperviscosity.
• The prevalence of hyperlipidemia varies by population and is influenced by factors such as diet, genetics, and lifestyle.

Dehydration-Related Hyperviscosity:

• Dehydration-related hyperviscosity can occur in various clinical settings, such as severe dehydration due to conditions like severe diarrhea, heatstroke, or inadequate fluid intake.
• The incidence of dehydration-related hyperviscosity depends on the prevalence of the underlying causes of dehydration and may vary widely.

It’s important to note that while these conditions are relatively rare individually, they collectively contribute to cases of hyperviscosity syndrome. Additionally, advances in the diagnosis and management of these underlying conditions have improved outcomes for affected individuals. The epidemiology of hyperviscosity syndrome itself is not well-documented separately from the conditions that lead to it.

Physicians typically encounter hyperviscosity as a complication in patients with the aforementioned underlying diseases. Therefore, understanding the epidemiology of the individual conditions associated with hyperviscosity is essential for recognizing and managing this syndrome in clinical practice.

Anatomy

Pathophysiology

Hyperviscosity syndrome is a clinical condition characterized by an increase in the viscosity (thickness or stickiness) of the blood due to a high concentration of macromolecules, such as proteins or lipids. This increased blood viscosity can impede normal blood flow and lead to a range of clinical symptoms and complications. The pathophysiology of hyperviscosity syndrome is closely linked to the underlying conditions that cause it. Here is an overview of the pathophysiology based on the primary underlying causes:

Multiple Myeloma and Waldenström Macroglobulinemia:

• In multiple myeloma, there is an overproduction of monoclonal (identical) immunoglobulins (antibodies) or fragments of immunoglobulins, particularly IgG or IgA.
• In Waldenström macroglobulinemia, there is an excess production of IgM immunoglobulins (macroglobulins).
• The accumulation of these abnormal immunoglobulins in the blood can result in increased blood viscosity.
• These proteins can form aggregates or precipitates at lower temperatures, further increasing blood viscosity, particularly in cooler parts of the body.

Polycythemia Vera:

• Polycythemia vera is characterized by the overproduction of red blood cells, white blood cells, and platelets.
• The increased number of red blood cells contributes to elevated hematocrit levels and increased blood viscosity.
• Elevated red blood cell counts can also lead to blood flow disturbances and microvascular issues.

Cryoglobulinemia:

• Cryoglobulinemia is characterized by the presence of abnormal proteins called cryoglobulins in the blood.
• Cryoglobulins can precipitate and form clumps in response to cold temperatures, leading to increased blood viscosity.
• The clumping of cryoglobulins can obstruct blood vessels and impair circulation.

Hyperlipidemia:

• Elevated levels of lipids (fats), particularly triglycerides, in the blood can increase blood viscosity.
• Triglycerides can accumulate in the plasma and make the blood thicker and stickier.

Dehydration-Related Hyperviscosity:

• Severe dehydration can result in decreased plasma volume, leading to increased hematocrit and blood viscosity.
• Dehydration reduces the fluid component of blood, making it more concentrated and viscous.

Clinical Consequences:

• Increased blood viscosity can impair blood flow in various organs and tissues, leading to a range of clinical manifestations.
• Common clinical symptoms of hyperviscosity syndrome include visual disturbances (due to retinal vein congestion), neurological symptoms (headaches, dizziness, confusion, and even seizures), mucosal bleeding (epistaxis, gum bleeding), and symptoms related to impaired blood flow to organs.
• Severe hyperviscosity can lead to thrombotic events, including strokes, heart attacks, and other ischemic complications.

The pathophysiology of hyperviscosity syndrome is primarily driven by the underlying conditions that cause increased blood viscosity. Therefore, treatment and management of the syndrome focus on addressing the specific underlying disorder responsible for the viscosity abnormalities. This may include chemotherapy for hematological malignancies, therapeutic plasma exchange (plasmapheresis) to remove abnormal proteins or lipids, and addressing dehydration or hyperlipidemia, as appropriate.

Etiology

Hyperviscosity syndrome is a clinical condition characterized by an increase in the viscosity (thickness or stickiness) of the blood, typically due to an elevated concentration of macromolecules within the blood plasma. The underlying etiology of hyperviscosity syndrome is closely related to the specific conditions or factors that lead to an excess accumulation of these macromolecules. Here are some of the key etiological factors associated with hyperviscosity syndrome:

Multiple Myeloma:

• Multiple myeloma is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells in the bone marrow.
• Plasma cells produce immunoglobulins (antibodies), and in multiple myeloma, there is often overproduction of monoclonal (identical) immunoglobulins, particularly IgG or IgA.
• The accumulation of these abnormal immunoglobulins in the blood can increase its viscosity, contributing to hyperviscosity syndrome.

Waldenström Macroglobulinemia:

• Waldenström macroglobulinemia is a rare type of non-Hodgkin lymphoma characterized by the excessive production of IgM immunoglobulins (macroglobulins).
• Elevated levels of IgM in the blood can significantly increase blood viscosity, particularly in cooler parts of the body where these immunoglobulins can precipitate or form clumps.

Polycythemia Vera:

• Polycythemia vera is a myeloproliferative disorder characterized by the overproduction of red blood cells, white blood cells, and platelets.
• The increased number of red blood cells and elevated hematocrit levels contribute to the increased viscosity of the blood.

Cryoglobulinemia:

• Cryoglobulinemia refers to the presence of abnormal proteins called cryoglobulins in the blood.
• Cryoglobulins can precipitate or form clumps in response to cold temperatures, further increasing blood viscosity.
• This condition can be associated with various underlying disorders, including hepatitis C virus (HCV) infection.

Hyperlipidemia:

• Elevated levels of lipids (fats), particularly triglycerides, in the blood can lead to increased blood viscosity.
• Triglycerides can accumulate in the plasma, making the blood thicker and stickier.

Dehydration-Related Hyperviscosity:

• Severe dehydration can result in reduced plasma volume, leading to increased hematocrit and blood viscosity.
• Dehydration causes the blood to become more concentrated and viscous.

Other Factors:

• Certain rare genetic conditions and disorders may also lead to elevated blood viscosity.
• In some cases, medications or treatments, such as intravenous immunoglobulin (IVIG) therapy, may transiently increase blood viscosity.

Genetics

Prognostic Factors

The prognosis of hyperviscosity syndrome largely depends on several factors, including the underlying cause of increased blood viscosity, the severity of symptoms, and the timeliness of diagnosis and treatment. Here are some key prognostic factors that can influence the outcome of hyperviscosity syndrome:

Underlying Condition: The specific underlying condition responsible for increased blood viscosity is a critical determinant of prognosis. Conditions such as multiple myeloma, Waldenström macroglobulinemia, and polycythemia vera have varying prognoses based on their natural histories and responses to treatment.

Severity of Hyperviscosity: The severity of hyperviscosity-related symptoms, especially neurological and visual disturbances, can influence the prognosis. Severe or rapidly progressing symptoms may indicate a worse prognosis.

Early Diagnosis: Timely diagnosis and intervention are essential for a better prognosis. Prompt recognition of hyperviscosity syndrome and its underlying cause allows for more effective treatment and a reduced risk of complications.

Treatment Efficacy: The success of treatment in managing the underlying condition and reducing blood viscosity is a significant factor in the prognosis. Adequate treatment that addresses the root cause of hyperviscosity can lead to symptom resolution and improved outcomes.

Response to Plasmapheresis: For cases of severe hyperviscosity with neurological symptoms, the response to plasmapheresis (therapeutic plasma exchange) can impact the prognosis. Rapid relief of symptoms following plasmapheresis is a positive prognostic indicator.

Complications: The presence of complications related to hyperviscosity, such as thrombosis (clot formation), bleeding, or organ damage, can influence the prognosis. Early detection and management of complications are crucial.

Underlying Disease Progression: In cases where hyperviscosity is associated with hematological malignancies like multiple myeloma or Waldenström macroglobulinemia, the prognosis may be influenced by the progression of the underlying disease and its response to treatment.

Overall Health: The patient’s overall health and any preexisting medical conditions can impact the prognosis. Patients with other significant comorbidities may have a more complex clinical course.

Follow-Up and Monitoring: Regular follow-up and monitoring of the patient’s clinical and laboratory parameters are essential for assessing treatment response and disease progression. Adjustments to treatment plans can be made based on monitoring results.

Clinical History

Clinical history

Onset of Symptoms:

The clinical history often begins with the onset of symptoms related to increased blood viscosity. These symptoms may develop gradually or have a sudden onset.

Systemic Symptoms:

• Patients with hyperviscosity syndrome may experience a range of systemic symptoms, including fatigue, weakness, and malaise.
• Patients may also report generalized symptoms, such as weight loss and night sweats, which are not specific to hyperviscosity but can be associated with underlying conditions.

Neurological Symptoms:

• One of the hallmark features of hyperviscosity syndrome is neurological symptoms, which can vary in severity.
• Common neurological symptoms include headache (often severe), dizziness, vertigo, and confusion.
• Visual disturbances, such as blurred vision or changes in color perception, can also occur and may be due to retinopathy (retinal vein congestion) caused by impaired blood flow in the retinal vessels.

Bleeding and Mucosal Symptoms:

• Patients may experience mucosal bleeding, such as epistaxis (nosebleeds) or gum bleeding, due to impaired platelet function.
• Easy bruising and petechiae (small red or purple spots on the skin) may also occur.

Cardiovascular Symptoms:

Some patients may present with cardiovascular symptoms, such as chest pain or palpitations.

Joint and Muscle Symptoms:

Patients may report joint pain (arthralgia) and muscle pain (myalgia).

Constitutional Symptoms:

Constitutional symptoms, such as fever and night sweats, may be present, particularly if there is an underlying hematologic malignancy, like multiple myeloma or Waldenström macroglobulinemia.

Underlying Condition:

A detailed medical history may reveal underlying conditions or hematologic disorders, such as multiple myeloma, Waldenström macroglobulinemia, or polycythemia vera, which can lead to hyperviscosity syndrome.

Medications and Medical History:

• Inquiring about the patient’s medications, including any immunoglobulin therapy or anticoagulants, can provide important information.
• A thorough medical history helps identify risk factors and potential underlying causes.

Progression of Symptoms:

Patients may describe how their symptoms have evolved over time, including any recent changes in symptom severity or duration.

Examination of Symptoms:

Clinical examination findings, such as neurological signs, visual disturbances, or evidence of bleeding (e.g., petechiae), are essential components of the clinical history.

Response to Treatment (if applicable):

If the patient has already received treatment for hyperviscosity syndrome or its underlying cause, it’s important to document the response to treatment and any improvements in symptoms.

Physical Examination

Physical examination

The physical examination of a patient with hyperviscosity syndrome focuses on identifying signs and symptoms that are characteristic of this condition, as well as assessing for complications related to increased blood viscosity. Here are key aspects of the physical examination when evaluating a patient for hyperviscosity syndrome:

General Appearance:

Observe the patient’s general appearance for signs of fatigue, weakness, or malaise, which are common systemic symptoms associated with hyperviscosity.

Vital Signs:

Measure and record vital signs, including blood pressure, heart rate, respiratory rate, and body temperature.

Neurological Assessment:

• Assess the patient’s neurological status, as neurological symptoms are a hallmark feature of hyperviscosity syndrome.
• Pay close attention to the patient’s mental status, including level of alertness and orientation.
• Evaluate for symptoms such as headache, dizziness, vertigo, confusion, and altered consciousness.
• Conduct a thorough examination of cranial nerves, including testing visual acuity, extraocular movements, and pupillary responses.
• Test for coordination, gait abnormalities, and motor strength.
• Check for signs of retinopathy, including retinal hemorrhages, venous dilation, and flame-shaped hemorrhages.

Ophthalmological Examination:

A detailed eye examination may be necessary to assess visual disturbances and retinal changes.

Fundoscopy can help detect retinal vein congestion or other ophthalmological abnormalities.

Bleeding and Mucosal Examination:

• Examine the patient for any signs of mucosal bleeding, such as epistaxis (nosebleeds), gum bleeding, or petechiae (small red or purple spots on the skin).
• Inspect the oral mucosa for signs of bleeding.

Cardiovascular Examination:

• Assess the cardiovascular system, including auscultation of the heart for any abnormal heart sounds (murmurs) or rhythm disturbances.
• Evaluate for chest pain or palpitations, which may be associated with hyperviscosity-related complications.

Musculoskeletal Examination:

Assess for joint pain (arthralgia) or muscle pain (myalgia), which some patients with hyperviscosity syndrome may experience.

Skin Examination:

Examine the skin for signs of petechiae, ecchymoses (bruises), or purpura (larger areas of bleeding beneath the skin).

Abdominal Examination:

Perform an abdominal examination to assess for hepatomegaly (enlarged liver) or splenomegaly (enlarged spleen), which may be associated with certain underlying conditions.

Lymph Node Examination:

Palpate the lymph nodes to check for lymphadenopathy, as lymph node enlargement can be associated with underlying diseases.

Respiratory Examination:

While respiratory symptoms are not typically a direct result of hyperviscosity syndrome, it’s important to assess the patient’s respiratory rate and lung sounds, as underlying conditions may be contributing to symptoms.

Examination of Skin Lesions (if present):

In some cases, skin lesions or rashes may be present and should be examined for characteristics that can aid in diagnosis.

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Primary Causes of Hyperviscosity:

• Multiple Myeloma: Multiple myeloma, a type of hematologic cancer, often leads to hyperviscosity due to the overproduction of monoclonal immunoglobulins (IgG or IgA).
• Waldenström Macroglobulinemia: This rare lymphoma is characterized by the production of excessive IgM immunoglobulins (macroglobulins), resulting in hyperviscosity.
• Polycythemia Vera: Polycythemia vera involves the overproduction of red blood cells, which can increase blood viscosity.

Other Hematologic Disorders:

Various hematologic conditions, such as essential thrombocythemia or myelofibrosis, can also lead to increased blood viscosity. These disorders are part of the myeloproliferative neoplasms and can present with symptoms similar to hyperviscosity.

Dehydration-Related Disorders:

Conditions or situations that cause severe dehydration, such as excessive vomiting, diarrhea, or insufficient fluid intake, can result in increased hematocrit levels and thickened blood. Dehydration can mimic the symptoms of hyperviscosity.

Autoimmune Disorders:

• Systemic Lupus Erythematosus (SLE): SLE can present with a wide range of symptoms, including fatigue, joint pain, and neurological symptoms, which may overlap with those seen in hyperviscosity syndrome.
• Rheumatoid Arthritis (RA): RA can cause joint pain and inflammation, sometimes mimicking the joint symptoms seen in hyperviscosity syndrome.

Neurological Conditions:

Some neurological conditions, such as migraine with aura or transient ischemic attacks (mini-strokes), can lead to visual disturbances, headaches, and neurological symptoms, which may be mistaken for hyperviscosity-related symptoms.

Ophthalmological Conditions:

Certain eye disorders, like retinal vein occlusion, can cause visual disturbances and retinopathy, which are also features of hyperviscosity syndrome.

Hypertension and Cardiovascular Disorders:

Conditions like hypertension or heart failure can result in symptoms such as headache, dizziness, and visual changes, which may be misattributed to hyperviscosity.

Medication Side Effects:

Some medications, including corticosteroids or certain immune-modulating drugs, can lead to side effects that mimic the symptoms of hyperviscosity.

Infections:

Infections, particularly those that affect the central nervous system (e.g., viral encephalitis or bacterial meningitis), can present with neurological symptoms and altered mental status similar to hyperviscosity syndrome.

Hypoglycemia:

Severe hypoglycemia (low blood sugar) can cause neurological symptoms, confusion, and visual disturbances, which may be mistaken for hyperviscosity-related symptoms.

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

The treatment of hyperviscosity syndrome involves addressing the underlying cause of increased blood viscosity, as well as managing the symptoms and complications associated with this condition. Treatment strategies may vary depending on the underlying condition responsible for hyperviscosity. Here are the key aspects of treatment:

Identify and Treat the Underlying Cause:

• The first and most crucial step in managing hyperviscosity syndrome is identifying and addressing the underlying condition responsible for increased blood viscosity.
• Common underlying conditions include multiple myeloma, Waldenström macroglobulinemia, polycythemia vera, cryoglobulinemia, hyperlipidemia, and others.
• Treatment approaches vary widely based on the specific underlying diagnosis.

Plasmapheresis or Therapeutic Plasma Exchange:

• Plasmapheresis, also known as therapeutic plasma exchange, is a procedure that involves removing a portion of the patient’s blood plasma and replacing it with a suitable replacement fluid, such as albumin or saline.
• Plasmapheresis is often used in cases of severe hyperviscosity syndrome to rapidly reduce the concentration of macromolecules in the blood, particularly when neurological symptoms are present.
• It provides immediate relief of symptoms and allows time to treat the underlying condition.

Chemotherapy and Targeted Therapy:

• Patients with underlying hematological malignancies, such as multiple myeloma or Waldenström macroglobulinemia, may require chemotherapy or targeted therapies to reduce the production of abnormal proteins or cells contributing to hyperviscosity.
• The choice of specific agents and treatment regimens depends on the type and stage of the malignancy.

Treatment of Polycythemia Vera:

For patients with polycythemia vera, treatment may involve phlebotomy (removal of excess blood), medications to reduce red blood cell production (e.g., hydroxyurea), and antiplatelet agents to prevent thrombosis.

Lipid-Lowering Therapy:

In cases of hyperviscosity associated with hyperlipidemia, lipid-lowering medications may be prescribed to reduce high levels of triglycerides or cholesterol.

Fluid Replacement and Hydration:

For patients with dehydration-related hyperviscosity, the primary treatment is rehydration to restore normal blood volume and reduce blood viscosity.

Symptomatic Treatment:

• Symptomatic management may include medications to relieve symptoms such as headache, pain, and bleeding.
• Antiplatelet agents may be considered in cases of bleeding or clotting complications.

Regular Monitoring:

• Patients with hyperviscosity syndrome require regular follow-up and monitoring to assess the response to treatment and the progression of the underlying condition.
• Adjustments to treatment may be necessary based on clinical and laboratory findings.

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

Future Trends

Media Gallary

References

https://emedicine.medscape.com/article/780258-overview